| Document |
Document Title |
|
WO/2021/239892A1 |
The present invention relates to methods of treating a condition wherein NO has a beneficial effect, wherein such treatment comprises administering certain mono- and/or bis nitrosylated propanediols, including compositions and formulatio...
|
|
WO/2021/239961A1 |
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stim...
|
|
WO/2021/239727A1 |
The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consi...
|
|
WO/2021/242913A1 |
A formulation is for use in enhancing permeation of vardenafil across a nasal mucosal membrane. The formulation includes vardenafil and an organic-aqueous solvent, which includes an alcohol, a polyether, diethylene glycol monoethyl ether...
|
|
WO/2021/238698A1 |
A traditional Chinese medicine composition and a traditional Chinese medicine sachet helping to boost mood, and an application thereof. The active components of the traditional Chinese medicine composition comprise the following raw mate...
|
|
WO/2021/237322A1 |
The present application pertains to the medical sector and comprises a biodegradable implant containing tadalafil in a polymer matrix. Said implant is inserted into the subcutaneous layer of the patient and provides continuous release of...
|
|
WO/2021/235977A1 |
The group of inventions relates to the field of medicine and the chemical and pharmaceutical industry, more particularly to a method for treating endometriosis and a pharmaceutical composition for realizing same. The method for treating ...
|
|
WO/2021/234271A1 |
The present invention relates to the use of a combination of a yeast of the species Saccharomyces cerevisiae, resveratrol and a curcuma extract for use in the treatment of a subject suffering or likely to suffer from endometriosis. The c...
|
|
WO/2021/228236A1 |
Provided are a deuterated tetrahydrothieno[3,4-d]pyrimidinedione compound as represented by formula (I) and a pharmaceutical composition containing the compound, or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solva...
|
|
WO/2021/231018A1 |
Described, among other things, are dosage form for administration to a subject, the dosage forms having at least eight phytonutrients selected from resveratrol, berberine, epigallocatechin gallate, quercetin, dandelion root extract powde...
|
|
WO/2021/224198A1 |
The invention relates to an oral dosage form of mifepristone of mifepristone oral formulation characterised in that said formulation comprises an amount selected from the group consisting of 75mg, 150 mg or 300 mg mifepristone, and said ...
|
|
WO/2021/223346A1 |
An application of a yam protein extract in preparation of a medication for treating erectile dysfunction. The yam protein extract is prepared by means of the following modes: homogenizing fresh yam with distilled water in an amount of 8-...
|
|
WO/2021/223966A1 |
The present invention relates to new uses and methods of treatment. More specifically, the invention relates to new uses of histone deacetylase inhibitors (HDACI) such as valproic acid (VPA), for enhancing in vitro fertilization (IVF) in...
|
|
WO/2021/224153A1 |
The present invention relates to pharmaceutical, dietary and/or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H2S) so to feed the redox buffer capacity and to boost the natural ability ...
|
|
WO/2021/221587A1 |
The present invention relates to a probiotic oil combination containing Lactobacillus rhamnosus, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus fermentus, Lactobacillus casei, Lactobacillus bre...
|
|
WO/2021/219581A1 |
The present invention presents new and innovative methods and systems for personalized, real-time diet and lifestyle recommendations for users that are seeking to improve their own fertility. In a preferred embodiment, the present invent...
|
|
WO/2021/218964A1 |
Use of an extract from Coriolus versicolor for the manufacture of a composition for the prevention and/or treatment of a vaginal or cervical disorder which is caused by an infectious agent, wherein the prevention or treatment comprises v...
|
|
WO/2021/215364A1 |
[Problem] To provide a medicament, etc., capable of preventing or treating intrauterine infection. [Solution] Intrauterine infection can be prevented or treated by orally administering silicon fine particles or placing the silicon fine p...
|
|
WO/2021/213358A1 |
Provided in the present invention are boron-containing compounds as represented by formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions including same, and an application of serving as a selective estroge...
|
|
WO/2021/209591A1 |
The present invention relates to a combined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reacti...
|
|
WO/2021/209471A1 |
The invention relates to an oral thin film, comprising a polymer matrix and ulipristal acetate as an active agent, wherein ulipristal acetate is dispersed in the polymer matrix and the polymer matrix is a matrix of water-soluble polymer ...
|
|
WO/2021/210636A1 |
Provided is a therapeutic agent for treating breast cancer which has developed resistance to the administration of antiestrogens and CDK 4/6 inhibitors, said therapeutic agent containing 5-((2-(4-(1-(2-hydroxyethyl)piperidine-4-yl)benzam...
|
|
WO/2021/207806A1 |
The present application pertains to the medical sector and comprises a biodegradable gestrinone implant in a polymer matrix. The implant is inserted subdermally and provides continuous release of the active substance for an extended peri...
|
|
WO/2021/208280A1 |
Provided is a dried fly larva and an application of same in the preparation of drugs for preventing and treating breast hyperplasia and for improving estrogen levels.
|
|
WO/2021/210673A1 |
Provided is an agent for improving the symptoms of menopause, the agent being useful for improving the symptoms of menopause. This agent for improving the symptoms of menopause contains delphinidin-3-rutinoside, cyanidin-3-rutinoside, ...
|
|
WO/2021/211386A1 |
In some aspects, disclosed herein are methods and compositions for treatment of erectile dysfunction using regenerative fibroblasts or cells derived from fibroblasts. Methods and compositions disclosed also include those for generating r...
|
|
WO/2021/206455A1 |
The present invention relates to a fraction extract of Melissa officinalis leaves, and a novel pharmaceutical composition and a food composition that include same.
|
|
WO/2021/207561A1 |
The present disclosure provides a pharmaceutical composition comprising therapeutically effective amounts of cyclobenzaprine and one or more agents, and methods of treating and/or preventing sexual dysfunction.
|
|
WO/2021/207168A1 |
This present disclosure relates to the use of syncytiotrophoblast-derived microvesicles for diagnosing and/or monitoring a subject with preeclampsia. Accordingly, this disclosure provides for methods for isolating, purifying, and/or dete...
|
|
WO/2021/207478A1 |
The present disclosure relates to compositions comprising an aqueous solution of at least about 70% by weight water in combination with selected fatty acid salts and optionally an alcohol and/or a cooling sensate, as well as methods of u...
|
|
WO/2021/201335A1 |
The present invention relates to a stamina-improving composition, and a stamina-improving functional food comprising same, especially, a stamina-improving natural tea. The present invention provides a stamina-improving composition compri...
|
|
WO/2021/201169A1 |
The purpose of the present invention is to improve sperm finding in male infertility. Provided is a composition for oral ingestion that contains creatine as an active ingredient.
|
|
WO/2021/198517A1 |
The invention relates to a composition comprising endometrial especially mesenchymal stem cells (EnMSC) for use in a method for the treatment of poor ovarian response and a method for banking endometrial especially mesenchymal stem cells.
|
|
WO/2021/198715A1 |
The present invention relates to a novel treatment method for the treatment of an infection caused by Neisseria gonorrhoeae, comprising administering gepotidacin or a pharmaceutically acceptable salt thereof to a human in need thereof, i...
|
|
WO/2021/196402A1 |
The present invention relates to the field of medicine, and provides a pharmaceutical composition. The pharmaceutical composition comprises: a Cordyceps sinensis extract and Guilu Erxian paste. According to a synergistic effect between t...
|
|
WO/2021/201532A1 |
The present invention relates to a composition for preventing, alleviating or treating female menopausal syndrome, containing a Rosa rugosa extract as an active ingredient, and improves estrogen levels and inhibits an increase in a body ...
|
|
WO/2021/198516A1 |
The invention relates to a composition comprising endometrial mesenchymal stem cells (EnMSC) for use in a method for the treatment of diminished ovarian reserve and a method for making a composition comprising endometrial mesenchymal ste...
|
|
WO/2021/194455A1 |
This invention is about the ferula elaeochytris root extract solution developed to be used particularly in pharmaceutical industry and for use in diabetic erectile disfunction treatment and its' characteristic is being consisted of the s...
|
|
WO/2021/194013A1 |
The present invention relates to a vaccine composition for eliminating boar taint, comprising a recombinant protein in which a cholera toxin B subunit (CTB) and a gonadotropin-releasing hormone (GnRH) are fused. More specifically, the pr...
|
|
WO/2021/194224A1 |
Provided in the present invention is a composition for ciliogenesis, containing a mesenchymal stem cell or a mesenchymal stem cell culture product. The mesenchymal stem cell or a mesenchymal stem cell culture product, according to the pr...
|
|
WO/2021/194142A1 |
The present invention relates to a vaccine composition which is for neutering or spaying an animal and comprises a recombinant protein in which cholera toxin B subunit (CTB) and gonadotropin-releasing hormone (GnRH) are fused. More speci...
|
|
WO/2021/187605A1 |
The present invention provides a compound useful as an active ingredient of a pharmaceutical composition for prophylaxis or treatment of premature ejaculation. Provided is a compound represented by formula (I) below [in the formula, A is...
|
|
WO/2021/188013A1 |
The invention relates to the field of medicine and may be used in treatment and prophylaxis of female reproductive system diseases. A method for treating endometriosis and concomitant formation of adhesions consists in an oral administra...
|
|
WO/2021/188012A1 |
What is claimed is a drug based on 3,3'-diindolylmethane and β-cyclodextrin, wherein the ingredient ratio is as follows: 3,3'-diindolylmethane 10-20 wt %, β-cyclodextrin 80-90 wt %. The method for producing said drug consists in dissol...
|
|
WO/2021/185728A1 |
The invention relates to biological biocomposites which comprise a collagen scaffold containing probiotics entrapped into the collagen scaffold and exopolysaccharides. The invention also relates to methods for obtaining the biocomposites...
|
|
WO/2021/179817A1 |
Disclosed is a progesterone emulsion injection, comprising progesterone, a grease solvent and water for injection, wherein the grease solvent is a mixture of oil for injection and benzyl benzoate, and the mass ratio of the oil for inject...
|
|
WO/2021/180143A1 |
The present invention provides a JAK kinase inhibitor and a preparation and application thereof, and the present invention specifically provides a compound having a structure represented in the following formula I, an enantiomer thereof,...
|
|
WO/2021/179087A1 |
The present disclosure relates to a composition comprising: i) terpenes in a diamond construction for delivering a specific aroma profile; and ii) optionally, at least one cannabinoid. The present disclosure also relates to methods of us...
|
|
WO/2021/177999A1 |
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for tr...
|
|
WO/2021/176387A1 |
The present invention relates to a composition comprising bacteria for use in the treatment or prevention of a pathology caused by or associated with an imbalance in the microbiota of the female reproductive system, preferably of the end...
|
